A quiet lab in Mountain View is switching telomerase on - briefly, then off - to reverse cellular aging inside scarred lungs, cirrhotic livers and failing marrow.
CAPTION: The founder measures a telomere trace on a screen the way other people check the weather. He has run this drug through his own veins. This is what conviction looks like at 4:8 on a weekday.
There is no fountain. There is a screen, a pipette, and a graph that used to only go down. At Rejuvenation Technologies, that graph now goes up - the plastic tips on the ends of chromosomes, the telomeres, growing longer instead of fraying away.
Every time a cell divides, its telomeres shorten a little. Do it enough times and the cell gives up - it stops dividing, starts misbehaving, and the tissue around it slowly turns to scar. That is a lot of what we call "aging." Rejuvenation Technologies' whole thesis fits in one sentence: what if you could add the length back?
The company was spun out of Helen Blau's lab at Stanford, where co-founder John Ramunas invented a way to do exactly that using modified mRNA - the same class of molecule that powered COVID vaccines. Instead of teaching cells to fight a virus, his mRNA tells them to briefly make telomerase, the enzyme that rebuilds telomeres. Then the mRNA clears, and the cell goes back to normal.
Scientists have known for decades that telomerase can lengthen telomeres. The problem: leave it on permanently and you invite cancer, which loves nothing more than immortal cells. That single risk stalled telomere medicine for a generation.
Rejuvenation Technologies' answer is timing. Their mRNA delivers a short pulse of telomerase - long enough to add years back to a cell's clock, short enough to disappear before it becomes dangerous. The company pairs it with proprietary lipid nanoparticles that steer the cargo to the organ that needs it, and away from the ones that don't.
Optimized telomerase (TERT) mRNA is wrapped in a tissue-targeted lipid nanoparticle.
The LNP routes to a chosen organ - lung, liver or marrow - minimizing off-target reach.
Cells briefly make telomerase and rebuild their telomeres, restoring capacity to divide.
The mRNA degrades. Telomerase switches off. No permanent expression, lower cancer risk.
Illustrative only. Depicts the directional effect of transient telomerase activation on telomere length reported in preclinical work - not clinical data.
Most longevity startups promise to treat everything and end up treating nothing. Rejuvenation Technologies went the other way - toward specific, deadly, age-driven diseases where the biology is undeniable and regulators pay attention.
A telomere-extension program aimed at compensated cirrhosis - regenerating liver cells that have run out of divisions.
Targets idiopathic pulmonary fibrosis by rejuvenating the lung's AT2 epithelial cells, where scarring begins.
Aims at bone-marrow failure and blood-forming stem cell disorders driven by telomere depletion.
PhD inventor of TERT mRNA telomere extension in Helen Blau's Stanford lab. Holds 50+ granted patents - and is serving as the first human subject in the company's own trial.
Stanford PhD in Genetics. Worked alongside Ramunas for over a decade on telomere extension and epigenetic reprogramming before co-founding the company.
Renowned Stanford stem-cell and muscle-biology professor whose lab produced the foundational telomere-extension science behind the platform.
TERT mRNA telomere extension is invented in Helen Blau's lab - reversing years of telomere shortening in days, in a dish.
Rejuvenation Technologies incorporates to translate the Stanford science into medicine.
$10.6M seed round led by Khosla Ventures; grants push initial funding past $15M.
FDA INTERACT clearance obtained; preclinical efficacy demonstrated across multiple organ systems.
Phase I data expected - the first real test of telomere extension in humans.
Return to that screen, that pipette, that once-downward line. Nothing about the room has changed. Everything about what the room means has.
For most of medical history, telomere shortening was scenery - something you watched happen and could not touch. Rejuvenation Technologies is trying to move it from the "inevitable" column to the "treatable" one, the way we once moved high cholesterol and untreated infection. That is a big claim, and Q3 2027 is when the first honest test arrives.
Until then, the work is unglamorous: nanoparticles to tune, organs to target, trials to run. But somewhere in Mountain View, someone is still watching a chromosome get a little younger - and this time, on purpose.